Table 3. PAGE-B model for predicting development of hepatocellular cancer in Caucasian patients treated with nucleotide/nucleoside analogues.

Variable	Score	Assessment of risk of HCC
Age
16-29	0	≤9: low
30-39	2
40-49	4	10-17: moderate
50-59	6
60-69	8	≥18: high
>70	10
Sex
Male	6
Female	0
Platelets
≥200,000	0
100,000-199,000	6
≤100,000	9

HCC: hepatocellular carcinoma.